4462. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
作者: Luca Richeldi.;Arata Azuma.;Vincent Cottin.;Christian Hesslinger.;Susanne Stowasser.;Claudia Valenzuela.;Marlies S Wijsenbeek.;Donald F Zoz.;Florian Voss.;Toby M Maher.; .
来源: N Engl J Med. 2022年386卷23期2178-2187页
Phosphodiesterase 4 (PDE4) inhibition is associated with antiinflammatory and antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis.
4463. Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
作者: Alberto Papi.;Bradley E Chipps.;Richard Beasley.;Reynold A Panettieri.;Elliot Israel.;Mark Cooper.;Lynn Dunsire.;Allison Jeynes-Ellis.;Eva Johnsson.;Robert Rees.;Christy Cappelletti.;Frank C Albers.
来源: N Engl J Med. 2022年386卷22期2071-2083页
As asthma symptoms worsen, patients typically rely on short-acting β2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma exacerbations. The use of a fixed-dose combination of albuterol and budesonide, as compared with albuterol alone, as rescue medication might reduce the risk of severe asthma exacerbation.
|